Rapid preparation and use of engineered tissue and scaffolds as individual implants

An ex vivo intraoperative method for manufacturing an individually engineered implant based on either a natural or a synthetic scaffold serving as a copy matrix for tissue to be generated as a result of one of a tissue defect and a tissue injury in a patient, the method comprising the steps:

• (i) providing one of the natural and the synthetic scaffold as a supporting matrix for growth of tissue cells;
• (ii) providing autologous stem cells obtained from the patient to be treated;
• (iii) providing healthy cells as copy cells obtained by biopsy from one of the defective tissue and the injured tissue of the patient to be treated;
• (iv) incubating stem cell preparation of step (ii) with a composition comprising a factor which stimulates stem cells and accelerates remodeling of tissue cells;
• (v) one of loading and injecting the cell preparation of step (iii) onto or into the scaffold matrix;
• (vi) incubating the pretreated scaffold matrix of step (v) in the presence of the pretreated stem cell preparation of step (iv) together with a composition comprising (a) a native factor recruiting and increasing the availability of stem cells, (b) a native factor that promotes differentiation of stem cells or its progenitor cells, and (c) the factor of step (iv);
• (vii) carrying out steps (iv)-(vi) under sterile conditions in either a bioreactor chamber or a laminar air flow cabinet over a period of 10 to 30 minutes;
• and
• (viii) using the so treated scaffold for implantation into the patient to be treated by a surgeon.

A method of using a preparation or composition comprising the steps of:

• (I) freshly preparing non-expanded autologous stem cells,
• (ii) selecting a factor that stimulates stem cells and accelerates remodeling of tissue cells from the group consisting of EPO and hGH,
• (iii) selecting a factor which recruits and increases the availability of stem cells from the group consisting of G-CSF and GM-CSF, and
• (iv) selecting a factor that promotes differentiation of either stem cells or its progenitor cells selected from the group consisting of TGRβ, VEGF, vitamin C and vitamin E,
• for manufacturing a medicament for the treatment of one of injured tissue and defected tissue in a patient either without or together with an implanted specific cell growth supporting scaffold, thereby achieving restitutio ad integrum.

A method of intraoperative preparing of autologues cells that induce, stimulate and promote differentiation and growth of tissue cells for one of defective tissue and injured tissue by either one of a natural and a synthetic scaffold in a patient, while prearranging and treating the patient for implantation of the scaffold into the patient, the cells being (a) autologous stem cells from bone marrow, tissue or blood of a patient suffering from one of a tissue defect, a tissue trauma and a tissue injury, and (b) healthy tissue cells as copy cells for coating the scaffold matrix to be implanted into the patient, the method comprising the steps:

• (I) identifying the damaged site in the patient;
• (ii) recruiting autologous stem cells from the patient to be treated by withdrawal by one of a bone marrow, a blood and bodily tissue;
• (iii) recruiting autologous tissue cells from the patient to be treated by biopsy of healthy surrounding or surviving cells from one of the defected tissue and the injured tissue, with these cells serving as template cells on the scaffold matrix;
• (iv) treating the stem cell concentrate of step (ii) ex vivo without having expanded them, with EPO or hGH or other factors that stimulate stem cells and accelerates remodeling of tissue cells for between 10 and 30 minutes in either a bioreactor or a laminar airflow cabinet located in the operation room under sterile conditions;
• (v) treating the template cells of step (iii) ex vivo, with at least one factor selected from the group consisting of EPO, hGH, GM-CSF, G-CSF, and TGFβ for between 10 and 30 minutes in either the bioreactor or the laminar airflow cabinet located in the operation room under sterile conditions;
• (vi) one of coating and injecting the scaffold ex vivo with the pretreated cells of steps (iv) and (v) for between 10 and 30 minutes in either the bioreactor or the laminar airflow cabinet located in the operation room under sterile conditions;
• (vii) prearranging the patient for implantation while carrying out steps (iv) to (vi);
• (viii) implanting the partially or completely coated scaffold of step (v) into the tissue defect or wound;
• and optionally
• (ix) applying by topical administration one of a gel-like composition, a glue-like composition and a glue-like formulation onto the implanted scaffold and onto the tissue in the environment of the implant, wherein the composition or formulation comprises the cells of steps (ii) and (iii) and one or more of the factors of step (v).